» Articles » PMID: 36464995

Linking Physical Activity to Breast Cancer Risk Via the Insulin/Insulin-like Growth Factor Signaling System, Part 2: The Effect of Insulin/Insulin-like Growth Factor Signaling on Breast Cancer Risk

Abstract

Perturbation of the insulin/insulin-like growth factor (IGF) signaling system is often cited as a mechanism driving breast cancer risk. A systematic review identified prospective cohort studies and Mendelian randomization studies that examined the effects of insulin/IGF signaling (IGF, their binding proteins (IGFBP), and markers of insulin resistance] on breast cancer risk. Meta-analyses generated effect estimates; risk of bias was assessed and the Grading of Recommendations Assessment, Development and Evaluation system applied to evaluate the overall quality of the evidence. Four Mendelian randomization and 19 prospective cohort studies met our inclusion criteria. Meta-analysis of cohort studies confirmed that higher IGF-1 increased risk of breast cancer; this finding was supported by the Mendelian randomization studies. IGFBP-3 did not affect breast cancer. Meta analyses for connecting-peptide and fasting insulin showed small risk increases, but confidence intervals were wide and crossed the null. The quality of evidence obtained ranged from 'very low' to 'moderate'. There were insufficient studies to examine other markers of insulin/IGF signaling. These findings do not strongly support the biological plausibility of the second part of the physical activity-insulin/IGF signaling system-breast cancer pathway. Robust conclusions cannot be drawn due to the dearth of high quality studies. See related article by Swain et al., p. 2106.

Citing Articles

[Progress in the Study of Mechanisms Clinically Relevant to Insulin Resistance 
and Lung Cancer].

Chen X, Chen P Zhongguo Fei Ai Za Zhi. 2024; 27(10):755-762.

PMID: 39631832 PMC: 11629090. DOI: 10.3779/j.issn.1009-3419.2024.106.27.


Fixed-Seat Rowing versus Sliding-Seat Rowing: Effects on Physical Fitness in Breast Cancer Survivors.

Gavala-Gonzalez J, Real-Perez M, Benitez-Garcia L, Fernandez-Garcia J Cancers (Basel). 2024; 16(12).

PMID: 38927913 PMC: 11201945. DOI: 10.3390/cancers16122207.


Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case-cohort analysis.

Albers F, Lou M, Dashti S, Swain C, Rinaldi S, Viallon V Cancer Causes Control. 2024; 35(6):921-933.

PMID: 38363402 PMC: 11130059. DOI: 10.1007/s10552-024-01856-6.


Antidiabetic Drugs in Breast Cancer Patients.

Garczorz W, Kosowska A, Francuz T Cancers (Basel). 2024; 16(2).

PMID: 38254789 PMC: 10813754. DOI: 10.3390/cancers16020299.


Linking Physical Activity to Breast Cancer via Inflammation, Part 2: The Effect of Inflammation on Breast Cancer Risk.

Lou M, Drummond A, Swain C, Milne R, English D, Brown K Cancer Epidemiol Biomarkers Prev. 2023; 32(5):597-605.

PMID: 36867866 PMC: 10150245. DOI: 10.1158/1055-9965.EPI-22-0929.


References
1.
Tin Tin S, Reeves G, Key T . Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank. Br J Cancer. 2021; 125(1):126-134. PMC: 8257641. DOI: 10.1038/s41416-021-01392-z. View

2.
Pollak M, Polychronakos C, Yousefi S, Richard M . Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun. 1988; 154(1):326-31. DOI: 10.1016/0006-291x(88)90688-2. View

3.
Kenney N, Dickson R . Growth factor and sex steroid interactions in breast cancer. J Mammary Gland Biol Neoplasia. 1996; 1(2):189-98. DOI: 10.1007/BF02013642. View

4.
Lero M, Shaw L . Diversity of insulin and IGF signaling in breast cancer: Implications for therapy. Mol Cell Endocrinol. 2021; 527:111213. PMC: 8035314. DOI: 10.1016/j.mce.2021.111213. View

5.
Gunter M, Xie X, Xue X, Kabat G, Rohan T, Wassertheil-Smoller S . Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res. 2015; 75(2):270-4. PMC: 4657855. DOI: 10.1158/0008-5472.CAN-14-2317. View